Device Trial Radar · NCT07939581
Influence of SUPRA SDRM on the Healing of Chronic Wounds
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Aug 16, 2023
Primary completion
Feb 27, 2025
Study completion Jun 5, 2025
Sponsor
- Lead sponsor
- Polymedics Innovations Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn how SUPRA SDRM affects the healing of chronic wounds. SUPRA SDRM is a synthetic wound covering that slowly breaks down on the wound. The trial includes adults aged 18 to 80 with a leg or foot wound that has not healed for at least 3 months. As a small pilot trial, it helps plan larger trials. The main questions it aims to answer are: * How does the size of the wound change during 12 weeks of treatment? * How does the condition of the wound change? All participants receive SUPRA SDRM. There is no comparison group. Participants: * Receive SUPRA SDRM on their wound, changed once a week for up to 12 weeks * Visit the clinic weekly for wound photos, wound checks and wound measurements * Answer questions about their quality of life * Return for follow-up visits after 4 and 6 months
Conditions
- Chronic Wound
- Leg Ulcer
- Venous Leg Ulcer
- Diabetic Foot Ulcer
Interventions
SUPRA SDRMDevice
CE-marked, fully synthetic, biodegradable wound matrix made of a lactide-based terpolymer. Applied to the cleansed wound, covered with a wound contact layer and a secondary dressing, and changed once weekly for up to 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Remaining Wound AreaTime frame: Baseline and weekly (every 7 ± 2 days) up to week 12
- Wound Characteristics Assessed by the Hollander Wound Evaluation Scale (HWES)Time frame: Baseline and weekly (every 7 ± 2 days) up to week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Coremed - Joanneum Research
Graz, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.